Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 2.552
Filter
2.
São Paulo; s.n; 2021. 69 p. ilust, tabelas.
Thesis in Portuguese | LILACS, Inca | ID: biblio-1222633

ABSTRACT

O carcinoma epidermóide (CEC) é a neoplasia maligna mais frequente em cavidade oral, representando aproximadamente 90% de todos os cânceres da boca. Esta neoplasia tem origem no epitélio de revestimento bucal, e a depender do subtipo e da sua localização, pode apresentar tendência marcante de invasão do tecido ósseo adjacente. Existe uma interação entre osso e neoplasia, e atenção principal deve ser dada aos reguladores relacionados à osteoclastogênese. As moléculas RANK/RANKL/OPG são fundamentais neste processo, e juntamente com a IL-6, promovem formação e ativação de osteoclastos, com consequente promoção da invasão mandibular. Neste sentido, o objetivo do estudo foi avaliar as características clínicas, radiográficas e histopatológicas dos pacientes submetidos a mandibulectomia para tratamento do carcinoma epidermóide oral, e correlacionar/associar com a expressão gênica na neoplasia de marcadores reguladores da invasão óssea. Foi realizado um estudo retrospectivo de pacientes tratados com algum tipo de mandibulectomia no A.C. Camargo Cancer Center durante o período de1990 a 2015. Um total de 220 casos foi selecionado, e destes, foram extraídos 40 casos, posteriormente submetidos as etapas de análise molecular. A análise molecular foi realizada por PCR quantitativa em tempo real (qPCR), por meio da mensuração de mRNA para os genes estudados, calibrados pelo gene endógeno GAPDH e por um pool de controle composto por RNA não neoplásico. Dos 220 pacientes incluídos na pesquisa, 161 eram do sexo masculino, a idade média foi de 60 anos, e 53,6% eram etilistas e 66,8% tabagistas. A invasão óssea da mandíbula foi observada através do laudo anatomopatológico em 77 pacientes, e foi associada à presença de margens comprometidas/exíguas e a localização da lesão (gengiva inferior, rebordo e região retro-molar). Ao final do estudo, 127 pacientes foram a óbito, e a média de sobrevida foi de 96,92 meses. Parâmetros clínicos, dos exames de imagem e histopatológicos foram significantemente associados com a sobrevida global, principalmente - tamanho do tumor, infiltração perineural, invasão óssea (imagem e anatomopatológico). Na análise multivariada, apenas invasão óssea e infiltração perineural aumentaram risco de óbito nos pacientes. Na análise molecular de expressão gênica foi possível avaliar que das 36 amostras do gene RANK, 16 eram downreguladas. Para RANKL, das 37 amostras, 28 estavam super expressas. Das 35 do gene da IL-6, 19 amostras eram downreguladas. E por fim, das 37 amostras do gene da OPG, 16 tinham expressão normal. A avaliação de associação entre a expressão dos genes analisados demostrou que o gene da IL-6 está associado a presença de invasão óssea, e que existe uma associação significativa entre as expressões do RANK, RANKL, OPG e IL-6. Maior sobrevida dos pacientes foi associada significativamente a uma expressão mais baixa de IL-6 (108,5 meses). Conclui-se que a invasão mandibular interfere na sobrevida global dos pacientes, e que este mecanismo de invasão óssea está associado com a expressão gênica dos genes RANK, RANKL, OPG e IL-6. A IL-6 downregulada nas células malignas está associada com maior sobrevida


Oral Squamous Cell Carcinoma (OSCC) is the most frequent malignant neoplasm in the oral cavity, representing 90% of all oral cancers. The tumor usually arises within the epithelium lining of the oral cavity, and in cases of certain subtype or location may reveal a tendency for invasion of the surrounding bone tissue. There is a relation between tumor and bone, and more attention should be given to the events related to osteoclastogenesis. The molecules RANK/RANKL/OPG are crucial in this process, and together with IL-6, promotes the formation and activation of osteoclasts, with influence on the mandibular invasion process. In this way, the aim of this study was to evaluate the clinical, demographic, imaging, and histopathology data of patients diagnosed with OSCC treated by mandibulectomy. Also, analyze the gene expression condition of the genes RANK, RANKL, OPG, and IL-6 on the tumor. A retrospective study was conducted on patients treated with mandibulectomy at the A.C. Camargo Cancer Center, between 1990 and 2015. Two hundred and twenty cases were retrieved, and 40 of them were selected for gene expression analysis. The mRNA expressions of the selected genes were determined by real-time polymerase chain reaction, extracted from the tumor, and calibrated by endogenous GAPDH and a control pool of non-neoplastic RNA. Among 220 patients, 161 were male, with a mean age of 60 years. 53.6% were alcohol users and 66.8% tobacco users. Mandible bone invasion was reported on 77 histopathology reports and associated with compromised margins and the site of the lesion (gingiva, alveolar ridge, and retromolar region). One hundred and twenty-seven patients died of the disease, and the mean overall survival rate was 96.92 months. Overall survival was associated with clinical, imaging, and pathological parameters, especially, tumor size, perineural growth, and bone invasion (both imaging and pathologic). Multivariate analysis revealed higher risk of death only to bone invasion and perineural growth. Gene expression analysis revealed - 16 downregulation of 36 RANK samples evaluated; 28 overexpression of 37 RANKL samples evaluated; 19 downregulation of 35 IL-6 analyzed, and 16 normal expression of 37 OPG samples evaluated. Association analysis revealed that IL-6 expression is associated with bone invasion, and there is also a significant association among the expression of RANK, RANKL, OPG, and IL-6. Higher overall survival rate was associated with an IL-6 down expression (108;5 months). In conclusion, mandibular invasion interferes with the patient's overall survivall rate, and the bone invasion mechanism is associated with gene expression of RANK, RANKL, OPG, and IL-6 on the tumor. IL-6 in downregulation expressed by malignant cells is associated with higher overall survivor rates


Subject(s)
Humans , Female , Pregnancy , Adult , Middle Aged , Prognosis , Carcinoma, Squamous Cell , Interleukin-6 , Receptor Activator of Nuclear Factor-kappa B , Osteoprotegerin , Mandible
3.
Clinics ; 76: e2690, 2021. tab, graf
Article in English | LILACS | ID: biblio-1278911

ABSTRACT

This study aimed to explore the relationship between plasma interleukin 6 (IL-6) levels, adverse cardiovascular events, and the severity of acute coronary syndrome (ACS). A literature review was performed of studies regarding IL-6 and ACS extracted from databases including EMBASE, Cqvip, MEDLINE, Web of Knowledge, PubMed, Cochrane Library, China National Knowledge Infrastructure, and Wanfang data. The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the literature. The literature was screened, its quality was evaluated, and relevant data were extracted for performing meta-analysis using RevMan software (version 5.3). A total of 524 studies were included in the initial survey. After several rounds of screening and analysis, six studies met the inclusion criteria and underwent meta-analysis using a fixed-effect model. Patients were divided into non-severe and severe groups based on the concentration of high-sensitivity C-reactive protein. Meta-analysis of the relationship between IL-6 and the severity of ACS showed that the plasma IL-6 level of patients in the severe group was significantly higher than that of patients in the non-severe group (p<0.00001). Additionally, patients with experience of major adverse cardiovascular events had significantly higher plasma IL-6 levels than did patients without experience of such events (p<0.00001). In summary, patients with ACS and high IL-6 levels tended to be in a critical condition, with a higher risk of adverse cardiovascular events and worse prognosis. Thus, IL-6 levels could indicate whether patients with ACS may have adverse cardiovascular events and determine the severity of ACS.


Subject(s)
Humans , Interleukin-6 , Acute Coronary Syndrome , Prognosis , C-Reactive Protein , China
4.
Article in Chinese | WPRIM | ID: wpr-879075

ABSTRACT

Dendrobii officinalis, with a definite effect of nourishing Yin and clearing heat, has been a folk habit for drinking after being mixed with water. Because its superfine powder has the advantages of high dissolution and convenient drinking, we observed the effect of D. officinalis superfine powder on metabolic hypertension model rats and its possible mechanism in this experiment, which can be used as a reference for its clinical application for hypertension. The overeating greasy-induced metabolic hypertension model was established with high-fat, high-sugar and high-purine diet. These rats were orally administered with 400 mg·kg~(-1) and 200 mg·kg~(-1) of D. officinalis superfine powder for 20 consecutive weeks. During this period, blood pressure, blood lipid, blood glucose, insulin and other related indexes of glucose and lipid metabolism were monitored; the levels of lipopolysaccharide(LPS), C-reactive protein(CRP), interleukin 6(IL-6) and other inflammatory mediators were measured; the levels of nitric oxide(NO) and endothelin-1(ET-1) were detected, and the histomorphological and ultrastructural changes of aorta were observed. In addition, the expression of LPS/TLR4 pathway-related molecules in aorta was determined. The results showed that long-term administration of D. officinalis superfine powder significantly reduced the levels of systolic blood pressure(SBP), diastolic blood pressure(DBP) and mean arterial pressure(MBP) in metabolic hypertension model rats, decreased the levels of total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-c), glucose(Glu), and insulin(INS) levels in blood, increased the contents of high density lipoprotein cholesterol(HDL-c),decreased the LPS, CRP, IL-6 and ET-1 levels in blood and increased NO content. Furthermore, it improved the abnormality of aortic histomorphology and endothelial ultrastructure, and inhibited the protein expression of TLR4, myeloid differentiation factor(MyD88), IL-6, interleukin-1 β(IL-1β), and tumor necrosis factor-α(TNF-α) as well as mRNA expression of TNF-α and IL-1β in aorta. In conclusion, D. officinalis superfine powder may improve the abnormal function and structure of blood vessels by inhibiting the activation of LPS/TLR4 pathway, thus playing a role against metabolic hypertension.


Subject(s)
Animals , Dendrobium/chemistry , Drugs, Chinese Herbal/pharmacology , Hyperphagia , Hypertension/drug therapy , Interleukin-6 , Powders , Rats , Tumor Necrosis Factor-alpha
5.
Article in Chinese | WPRIM | ID: wpr-878893

ABSTRACT

This study aims to investigate the potential mechanism of curcumin in mediating interleukin-6(IL-6)/signal transducer and activator of transcription 3(STAT3) signaling pathway to repair intestinal mucosal injury induced by 5-fluorouracil(5-FU) chemotherapy for colon cancer. SD rats were intraperitoneally injected with 60 mg·kg~(-1)·d~(-1) 5-FU for 4 days to establish a model of intestinal mucosal injury. Then the rats were randomly divided into model group(equal volume of normal saline), curcumin low, medium and high dose groups(50, 100, 200 mg·kg~(-1)), and normal SD rats were used as control group(equal volume of normal saline). Each group received gavage administration for 4 consecutive days, and the changes of body weight and feces were recorded every day. After administration, blood was collected from the heart, and jejunum tissues were collected. The levels of serum interleukin-1β(IL-1β) and tumor necrosis factor-α(TNF-α) were detected by ELISA, and at the same time, the concentration of Evans blue(EB) in jejunum was measured. Hematoxylin-eosin(HE) staining was used to observe the pathological state of jejunum, and the length of jejunum villi and the depth of crypt were measured. The positive expression levels of claudin, occludin and ZO-1 were detected by immunohistochemistry. Western blot was used to detect the protein expression of IL-6, p-STAT3, E-cadherin, vimentin and N-cadherin in jejunum tissues. The results showed that, curcumin significantly increased body weight and fecal weight(P<0.05 or P<0.01), decreased fecal score, EB concentration, IL-1β and TNF-α levels(P<0.05 or P<0.01) in rats. In addition, curcumin maintained the integrity of mucosal surface and villi structure of jejunum to a large extent, and reduced pathological changes in a dose-dependent manner. Meanwhile, curcumin could increase the positive expression of occludin, claudin and ZO-1(P<0.05 or P<0.01), repair intestinal barrier function, downregulate the protein expression of IL-6, p-STAT3, vimentin and N-cadherin in jejunum tissues(P<0.05 or P<0.01), and upregulate the protein expression of E-cadherin(P<0.05). Therefore, curcumin could repair the intestinal mucosal injury induced by 5-FU chemotherapy for colon cancer, and the mechanism may be related to the inhibition of IL-6/STAT3 signal and the inhibition of epithelial-mesenchymal transition(EMT) process.


Subject(s)
Animals , Colonic Neoplasms/drug therapy , Curcumin , Fluorouracil/toxicity , Interleukin-6/genetics , Intestinal Mucosa/metabolism , Rats , Rats, Sprague-Dawley , STAT3 Transcription Factor/metabolism , Signal Transduction
6.
Braz. arch. biol. technol ; 64: e21200179, 2021. tab, graf
Article in English | LILACS | ID: biblio-1153293

ABSTRACT

HIGHLIGHTS L. duriusculum n-BuOH extract reduces inflammatory responses both in vitro and in vivo. L. duriusculum n-BuOH extract inhibits NF-κB-dependent transcriptional responses. L. duriusculum n-BuOH extract decreases the expression of TNF-α and IL-6 genes.


Abstract Limonium duriusculum is used in folk medicine to treat inflammatory disorders and has gained attention due to its richness in apigenin. The present investigation was performed to evaluate and confirm its anti-inflammatory properties, in cell lines and animal models. The potential anti-inflammatory properties of n-butanol (n-BuOH) extract of L. duriusculum (BEL) and isolated apigenins were examined on NF-κB transcriptional activity in TNFα- or LPS-stimulated cells, and on in vivo acute inflammatory models (carrageenan induced paw edema and peritonitis). BEL treatment was able to inhibit the activity of an NF-κB reporter gene in HCT116 cells both in the absence and in the presence of exogenous TNFα, used as NF-κB pathway inducer. This anti-inflammatory effect was even more potent compared to Apigenin (APG1) and was confirmed using monocyte-derived THP-1 cells treated with LPS to stimulate NF-κB-dependent transcription of IL-6 and TNFα mRNAs. Apigenin7-O-β-(6''-methylglucuronide) (APG2) was instead inactive both in HCT116 and THP-1 cells. BEL (oral, 200 mg/kg) led to paw swelling inhibition, vascular permeability and peritoneal leukocyte and PN migration diminution. Apigenins (intraperitoneal, APG1, APG2: 20 mg/kg) also evoked a significant anti-edema effect, early vascular permeability and leukocyte influx reduction. Collectively, this study demonstrates for the first time the effectiveness of L. duriusculum to inhibit NF-κB-dependent transcriptional responses in HCT116 and THP-1 cells. In vivo studies also established that L. duriusculum possesses a potential anti-inflammatory effect, confirm its traditional, empirical use, that could be attributed to its richness in apigenin.


Subject(s)
Humans , Animals , Male , Rats , Plant Extracts/pharmacology , Plumbaginaceae/chemistry , Immunomodulation/drug effects , Anti-Inflammatory Agents/pharmacology , Interleukin-6 , Rats, Wistar , Models, Animal , THP-1 Cells
7.
Braz. j. med. biol. res ; 54(7): e10687, 2021. tab, graf
Article in English | LILACS | ID: biblio-1249315

ABSTRACT

Helicobacter pylori (H. pylori) induces an intense inflammatory response, mediated by proinflammatory cytokines, including interleukin (IL)-6 and its membrane receptor (IL-6R), which activates important signaling pathways in the development of gastric disease and cancer. We investigated the gene and protein expression of IL-6 and IL-6R and the influence of polymorphisms rs1800795, rs1800796, and rs1800797 on its gene expression together with H. pylori infection. Furthermore, an in-silico analysis was performed to support our results. Gastric biopsies were obtained from patients with gastric symptoms and patients with gastric cancer (GC) and were divided into groups (Control, Gastritis, and Cancer). H. pylori was detected by PCR. Real-time-qPCR was employed to determine gene expression, and western blot assay was used to analyze protein expression levels. PCR-RFLP was used to characterize IL-6 polymorphisms. Bioinformatics analyses were performed using the Gene Expression Omnibus (GEO) database and GEO2R to screen out differentially expressed genes (DEGs). H. pylori was detected in 43.3% of the samples. Statistically significant differences were found for IL-6 (P=0.0001) and IL-6R (P=0.0005) genes among the three groups, regardless of the presence of H. pylori. Among patients with H. pylori infection, the IL-6 and IL-6R gene and protein expressions were significantly increased, highlighting IL-6 gene overexpression in patients with GC. No statistically significant differences were found for the rs1800795, rs1800796, and rs1800797 polymorphisms compared to IL-6 gene expression. The results indicated that the IL-6 polymorphisms do not influence its expression, but IL-6 and IL-6R expression seems to be altered by the presence of H. pylori.


Subject(s)
Humans , Stomach Neoplasms/genetics , Helicobacter pylori , Helicobacter Infections/genetics , Interleukin-6/genetics , Gastritis/genetics , Interleukin-8 , Gastric Mucosa
8.
An. Fac. Cienc. Méd. (Asunción) ; 53(3): 131-146, 20201201.
Article in English | LILACS | ID: biblio-1177997

ABSTRACT

La pandemia de COVID-19, causada por SARS-CoV-2, es considerara la mayor emergencia sanitaria en un siglo. Clínicamente, la mayoría de los pacientes tienen síntomas leves a moderados. Sin embargo, pacientes de edad avanzada o con comorbilidades pueden desarrollar una de las complicaciones más severas de COVID-19, es decir, el síndrome de tormenta de citoquinas. Actualmente, no existen tratamientos aprobados para SARS-CoV-2. Mientras tanto, las estrategias terapéuticas se basan en la experiencia previa con otros virus. En este artículo se revisarán los diferentes agentes terapéuticos propuestos para el tratamiento de COVID-19 basados en el bloqueo e inhibición del ciclo de vida viral de SARS-CoV-2, y para el tratamiento del síndrome de tormenta de citoquinas. Se realizó una revisión narrativa mediante búsqueda en la base de datos PubMed. Entre los principales objetivos terapéuticos contra el SARS-CoV-2 están la proteína estructural principal Spike y las enzimas virales proteasa similar a la 3-quimotripsina, la proteasa viral similar a la papaína y la ARN-polimerasa dependiente de ARN. Remdesivir, un antiviral análogo a la adenosina que inhibe a la ARN-polimerasa dependiente de ARN, es considerado el fármaco más prometedor en el tratamiento de COVID-19. No obstante, su eficacia aún no se ha determinado. En el síndrome de tormenta de citoquinas, la lesión tisular causada por el virus puede inducir la producción exagerada de citoquinas proinflamatorias como la interleucina-6. Tocilizumab, un anticuerpo monoclonal que bloquea receptores de interleucina-6 y corticosteroides como la metilprednisolona pueden ser opciones terapéuticas en el tratamiento de la severidad del síndrome.


The COVID-19 pandemic, caused by SARS-CoV-2, is considered as the major health emergency in a century. Clinically, most patients have mild to moderate symptoms. Nevertheless, elderly or with comorbidities patients may develop one of the most severe complication of COVID-19, that is, the cytokine storm syndrome. Currently, there are no approved treatments for SARS-CoV-2. Meanwhile, therapeutic strategies are based on previous experience with other viruses. This article will review the different therapeutic agents proposed for the treatment of COVID-19 based on the blocking and inhibition of the viral life cycle of SARS-CoV-2, and for the treatment of cytokine storm syndrome. A narrative review was performed by searching in the PubMed database. Among the main therapeutic target against SARS-CoV-2 are the major structural protein Spike and viral enzymes 3-chymotrypsin-like protease, viral papain-like protease, and RNA-dependent RNA polymerase. Remdesivir, an adenosine analogue antiviral that inhibits RNA-dependent RNA polymerase, is considered the most promising drug in the treatment of COVID-19. Nonetheless, its efficacy has not yet been determined. In the cytokine storm syndrome, the tissue injury caused by the virus may induce the exaggerated production of pro-inflammatory cytokines such as interleukin-6. Tocilizumab, a monoclonal antibody that blocks interleukin-6 receptors, and corticosteroids such as methylprednisolone may be therapeutic options in treating the severity of the syndrome.


Subject(s)
RNA-Dependent RNA Polymerase , RNA , Methylprednisolone , Adenosine , Cytokines , Interleukin-6 , Adrenal Cortex Hormones , Coronavirus Infections , Betacoronavirus , Pandemics , Goals , Life Cycle Stages
9.
Rev. argent. reumatolg. (En línea) ; 31(3): 40-50, set. 2020. ilus, tab
Article in Spanish | LILACS, BINACIS | ID: biblio-1149675

ABSTRACT

Introducción: La artritis reumatoidea se caracteriza por inflamación de la membrana sinovial debido al infiltrado de células inmunitarias que secretan citocinas relacionadas a perfil Th17 como IL-22 e IL-6. La dinámica de estas citocinas durante el tratamiento permanece incomprendida. El objetivo fue evaluar los niveles séricos y en líquido sinovial (LS) de IL-22 e IL-6, correlacionarlos con diferentes parámetros bioquímicos y clínicos y medir sus cambios post-tratamiento. Material y métodos: Se estudiaron 77 pacientes con AR y 30 controles. A 30 pacientes se los evaluó nuevamente luego de 3 meses de tratamiento y a 12 se les extrajo LS. Se midió VSG, PCR, FR, anti-CCPhs, IL-22 e IL-6. Se evaluó la actividad con DAS28 y respuesta al tratamiento con criterios EULAR. Resultados: IL-22 e IL-6 fueron similares entre pacientes y controles. Sus niveles disminuyeron luego del tratamiento, principalmente en pacientes respondedores. IL-22 fue menor e IL-6 mayor en LS que en sangre. IL-6 correlacionó positivamente con PCR y anti-CCPhs. Los niveles de VSG, PCR y DAS28 fueron mayores en pacientes con valores dosables de IL-6 que en no dosables. Conclusión: En pacientes con valores basales dosables de IL-22 e IL-6, los niveles de estas citocinas podrían utilizarse como marcador adicional de respuesta al tratamiento.


Introduction: Rheumatoid arthritis is characterized by synovium inflammation due to the infiltration of immune cells that secrete Th17 cytokines like IL-22 and IL-6. The dynamics of these cytokines during the treatment remain unknown. The aim of this study was to evaluate the levels of IL-22 and IL-6 serum and synovial fluid (SF) in correlation with different biochemical and clinical parameters and treatment-associated changes. Material and methods: Seventy-seven RA patients and 30 controls were recruited. Thirty patients were evaluated after 3 months of treatment and SF was collected of 12 patients. ESR, CRP, RF, anti-CCP hs, IL-22 e IL-6 were measured. DAS28 was used to assess disease activity and response to treatment followed EULAR criteria. Results: There were not differences in serum IL-22 and IL-6 levels between patients and controls. Cytokine levels decreased after treatment, mainly in responder patients. IL-22 was decreased and IL-6 was increased in SF compared to serum. IL-6 correlated positively with CRP and anti-CCPhs. ESR, CRP and DAS28 were increased in patients with detectable IL-6 compared to those with undetectable IL-6. Conclusion: In patients with detectable serum IL-22 and IL-6 levels before treatment initiation, follow-up of cytokine levels could be an useful additional tool to evaluate treatment response.


Subject(s)
Arthritis, Rheumatoid , Therapeutics , Interleukins , Interleukin-6 , Inflammation
11.
Brasília; s.n; 27 abr. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1097410

ABSTRACT

Essa é uma produção do Departamento de Ciência e Tecnologia (Decit) da Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (SCTIE) do Ministério da Saúde (Decit/SCTIE/MS), que tem como missão promover a ciência e tecnologia e o uso de evidências científicas para a tomada de decisão do SUS, tendo como principal atribuição o incentivo ao desenvolvimento de pesquisas em saúde no Brasil, de modo a direcionar os investimentos realizados em pesquisa pelo Governo Federal às necessidades de saúde pública. Informar sobre as principais evidências científicas descritas na literatura internacional sobre tratamento farmacológico para a COVID-19. Além de resumir cada estudo identificado, o informe apresenta também uma avaliação da qualidade metodológica e a quantidade de artigos publicados, de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, entre outros). Foram encontrados 9 artigos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Chloroquine/therapeutic use , Interleukin-6/therapeutic use , Interleukin-1/therapeutic use , Clarithromycin/therapeutic use , Obesity Management/organization & administration , Hydroxychloroquine/therapeutic use
12.
s.l; IETSI; 26 mar. 2020.
Non-conventional in Spanish | LILACS, BRISA | ID: biblio-1096320

ABSTRACT

INTRODUCCIÓN: Al momento se tienen propuestas de tratamiento para el COVID-19, en las que se incluye el uso de interferón (Lu 2020; Li and De Clercq 2020). Dentro del espectro de los medicamentos catalogados como interferón (IFN) tenemos IFN alfa o IFN alfa pegilado, IFN alfa 2a, IFN alfa 2b, IFN beta, IFN beta 1a, IFN beta 1b, e IFN gamma (Friedman 2008). De manera anecdótica, ante los brotes de MERS y SARS producidos en años previos, se investigó el uso de IFN como medida terapéutica (Sainz et al. 2004; Scagnolari et al. 2004). Sin embargo, dichos estudios corresponden a estudios in-vitro. En el estudio in vitro de Sainz y col. 2004 (Sainz et al. 2004), se encontró que sinérgicamente IFN beta e IFN gamma inhiben el crecimiento de los cultivos en placa del SARS-CoV, virus que causó el brote del 2003 en China; en el estudio in vitro de Scagnolari y col. 2005 (Scagnolari et al. 2004), se encontró que los IFN presentaban capacidad para inhibir el crecimiento en placa del SARS-CoV (principalmente de IFN beta e IFN gamma). Por otra parte, en una revisión sistemáticade Morra y col 2018 (Morra et al. 2018), donde se estudió el uso de IFN para el tratamiento de MERS-CoV, responsable del brote en Arabia Saudita en el 2012, en sus diferentes presentaciones (incluyendo IFN alfa-2a, IFN alfa-2b, e IFN beta-1a) en combinación con ribavirina, se encontró que no hubo diferencias significativas en desenlaces clínicos cuando se le comparó con otra terapia de soporte. Se observó que se suele utilizar IFN (IFN alfa-2a, IFN alfa-2b, e IFN beta1a) en combinación con ribavirina. En otro estudio tipo revisión sistemática de Momattin y col. 2019 (Momattin, Al-Ali, and Al-Tawfiq 2019), encontraron que no existe consenso para el tratamiento de MERS-CoV pues los estudios fueron heterogéneos y los resultados no concluyentes. En dicho estudio se utilizó IFN 1b en combinación con ribavirina. Debemos resaltar que existe una escasez de evidencia respecto al uso de interferón en COVID19, y la mayoría de la evidencia proviene de estudios in-vitro. GUÍAS DE PRÁCTICA CLÍNICA: La Guía de Medicina Integrativa de China Oriental para el manejo del nuevo coronavirus 2019, provee de información clínica y epidemiológica sobre el COVID 19. Dentro de las alternativas terapéuticas que se encuentran en investigación, menciona al interferón y la evidencia que proviene de estudios de ciencias básicas que encontraron que este medicamento puede frenar la replicación in-vitro del SARS-CoV (Sainz y col. 2004) (Scagnolari y col. 2005). El estudio de Sainz y col. del 2014 encontró que sinérgicamente IFN beta e IFN gamma inhiben el crecimiento de los cultivos en placa del SARS-CoV. El estudio de Scagnolari y col. del 2005, encontró que los IFN presentaban capacidad para inhibir el crecimiento en placa del SARS-CoV (principalmente de IFN beta e IFN gamma). La GPC no presenta recomendaciones respecto al uso de IFN (en ninguna presentación), solo indica que se encuentra en etapa experimental para el uso de pacientes con COVID-19. ESTUDIO SERIE DE CASOS: Lo que se presenta aqui es la experiencia de manejo de pacientes, quienes recibieron múltiples esquemas de tratamiento incluido el IFN. Por tanto, no podemos concluir que los resultados encontrados se deben al uso de IFN. Además, la metodología de una serie de casos no es la ideal para establecer que los pacientes mejoraron por el uso de IFN. Es necesario realizar ensayos clínicos para determinar como influye el IFN en el manejo clínico de pacientes con COVID19. ENSAYOS CLÍNICOS EN CURSO O NO PUBLICADOS REGISTRADOS EN CLINICALTRIALS.GOV: Ensayo clínico no publicado, en fase de reclutamiento de pacientes. NCT04254874 Abidol hydrochloride vs Abidol Hydrochloride combinado con atomización de Interferon PegIFN-α-2b, fase 4, en pacientes con neumonía viral COVID19. Patrocinador Tongji Hospital. A ser realizado en Wuhan, Hubei, China. Fecha estimada de término de estudio: 1ero de julio del 2020. Ensayo clínico no publicado, aún no inicia fase de reclutamiento de pacientes NCT04293887. Uso de interferón alfa-1b en pacientes con infección por COVID19, fase 1, patrocinador Tongji Hospital. Fecha estimada de término de estudio: 30 de junio del 2020. Ensayo clínico no publicado, aún no inicia reclutamiento de pacientes. NCT04275388. Inyección de Xiyanping vs Lopinavir / ritonavir, nebulización de interferon alfa, no aplica fase, en pacientes con neumonía viral COVID19. Patrocinador Jiangxi Qingfeng Pharmaceutical Co. Ltd. Fecha estimada de término de estudio: 14 de diciembre del 2021. Ensayo clínico no publicado, en fase de reclutamiento de pacientes NCT04276688. Lopinavir/ritonavir, ribavirina e interferón beta-1b, fase 2, patrocinador The University of Hong Kong. Fecha estimada de término de estudio: 31 de julio del 2022. EXPERIENCIA RECOGIDA DE HOSPITALES EN EL MUNDO: Debido a que la enfermedad por COVID19 inició en diciembre del 2019, algunos hospitales han recomendado el uso de IFN bajo las siguientes modalidades: España (Sociedad Española de Farmacia Hospitalaria al 18 de marzo 2020): (Sociedad Española de Farmacia Hospitalaria 2020). Se utiliza hasta que caiga la fiebre y no más de 14 días: Estados Unidos (Guía de manejo de COVID19 del Massachusetts Medical Hospital al 17 de marzo 2020): (Massachusetts General Hospital 2020). CONCLUSIONES: A la fecha, 24 de marzo del 2020, aun no se encuentran ensayos clínicos publicados con resultados de eficacia y seguridad respecto al uso del IFN en pacientes con COVID19, infectadas con el virus SARS-CoV-2. Como hecho anecdótico se toma la experiencia de uso de IFN en infecciones causadas por los virus SARS-CoV y MERS-CoV en años previos, los cuales comparten parte importante de su componente genético con el SARS-CoV-2. Encontramos resultados en estudios in-vitro donde el IFN mostró cierta capacidad de inhibir el crecimiento de los virus mencionados. Las recomendaciones de la GPC de Chan y col. (2020), se basa en estudios invitro realizados en el 2004 (Sainz et al. 2004; Scagnolari et al. 2004). La guía de Chan y col. (2020) indica que el uso de IFN en cualquiera de sus presentaciones no se encuentra recomendado para pacientes con infección por COVID-19 y su uso solo es experimental. Por otro lado, la GPC de National Health Commission & Stare Administration of Traditional Chinese Medicine recomienda incluir el uso de IFN-alfa pero no menciona la Encontramos una serie de casos en China (Wan et al. 2020) con 135 pacientes con COVID19 a quienes se le administró IFN más lopinavir/ritonavir, en combinación con antibióticos y corticoides. Alrededor del mes de seguimiento, 11.1% (n=15) de pacientes fueron dados de alta, la tasa de mortalidad a los 28 días de seguimiento fue de 2.5%. Este estudio constituye un primer aporte a la literatura científica sobre el manejo de pacientes con COVID19. Debido a que todos los pacientes del estudio recibieron IFN en combinación con lopinavir/ritonavir, no se puede discriminar si el efecto del IFN es favorable o no para pacientes con COVID19. Es necesario realizar ensayos clínicos para determinar cómo influye el IFN en el manejo clínico de pacientes con COVID19. fuente de donde se obtiene la evidencia para recomendar el uso de IFN. Encontramos que se están llevando a cabo varios ensayos clínicos (EC) respecto al uso de IFN para pacientes con COVID19. Los ensayos clínicos más próximos para finalizar son en julio del 2020. La intervención de interés en la experiencia en hospitales (Sociedad Española de Farmacia Hospitalaria 2020) (Massachusetts General Hospital 2020), por lo general, es dual. Es decir, combina la acción de un tipo de IFN junto a otro antiviral, que por lo general es ribavirina. Otros tipos de antivirales con los cuales se combina al IFN son los esteroides, lopinavir/ritonavir, o micofenolato mofetil. Encontramos guías de sociedades/hospitales internacionales donde actualmente tienen picos muy altos de pacientes con COVID19. Dichas guías incluyen en su algoritmo terapéutico al IFN en diferentes formas (IFN alfa-2b nebulizada e IFN beta-1b inyectable). Sin embargo, no existe ningún ensayo clínico a la fecha que respalde su uso, salvo la experiencia de manejo de pacientes en China. Por ello, son necesarios los resultados de los ensayos clínicos en curso. Por lo expuesto, al momento, no se encuentra que IFN en ninguna de sus presentaciones (IFN alfa o IFN alfa pegilado, IFN alfa 2a, IFN alfa 2b, IFN beta, IFN beta 1a, IFN beta 1b, o IFN gamma), tenga evidencia clínica que respalde una recomendación a favor como una alternativa de tratamiento para pacientes con COVID19. Se necesita de los resultados de los EC que se están realizando para conocer tanto su eficacia como su seguridad en pacientes con COVID19.


Subject(s)
Interleukin-6/therapeutic use , Coronavirus Infections/drug therapy , Interleukin-18/therapeutic use , Interferon alpha-2/therapeutic use , Technology Assessment, Biomedical , Cost Efficiency Analysis
13.
Acta bioquím. clín. latinoam ; 54(1): 29-38, mar. 2020. graf, tab
Article in Spanish | LILACS | ID: biblio-1130576

ABSTRACT

La calprotectina fecal se ha afianzado en los últimos años como un marcador útil de las patologías gastrointestinales. El objetivo de este estudio fue determinar los niveles de calprotectina fecal (CPF), interleuquina-6 (IL-6) y proteína C reactiva (PCR) en tres grupos de pacientes: con diagnóstico de novo de enfermedad celíaca, con diagnóstico previo y dieta libre de gluten (DLG) y un grupo control. Se colectaron muestras de 79 pacientes entre 18 y 65 años. A todos se les determinó CPF, IL-6 y PCR como marcadores de inflamación y anticuerpos anti-transglutaminasa IgA y anti-gliadinas desaminadas IgA e IgG como marcadores serológicos. Se encontraron valores significativamente incrementados de PCR en el grupo de novo (124,06 μg/g) comparados con el grupo con DLG (23,61 μg/g) y el grupo control (16,91 μg/g) respectivamente. No se encontraron diferencias entre el grupo con DLG y el negativo (control). Idéntico comportamiento se observó para IL-6 con valores en el grupo de novo de 2,39 μg/dL, 1,74 μg/dL en el grupo con DLG y 1,41 μg/dL en el control negativo. No se encontraron diferencias significativas en el análisis de resultados de PCR. Se encontró una excelente sensibilidad (98,0%) y especificidad (96,6%) en la capacidad de la CPF para diferenciar valores de anti-transglutaminasa IgA superiores o inferiores al punto de corte cuando se estimó el índice de Youden. Se podría considerar a la CPF como un posible marcador sensible para indicar inflamación intestinal de manera no invasiva en la enfermedad celíaca.


The determination of fecal calprotectin has been strengthened in recent years as a useful marker of gastrointestinal pathologies. The objective of this study was to determine the levels of fecal calprotectin (FCP), interleukin-6 (IL-6) and C-reactive protein (CRP) in three groups of patients: with de novo diagnosis of celiac disease, with previous diagnosis and gluten-free diet (GFD) and a control group. Samples were collected from 79 patients between 18 and 65 years old. In all cases, FCP, IL-6 and RCP were determined as markers of inflammation and anti-transglutaminase IgA and deaminated anti-gliadin IgA and IgG antibodies as serological markers. Significantly more increased FCP values were found in the de novo group (124.06 μg/g) than in the group with DLG (23.61 μg/g) and the control group (16.91 μg/g). No differences were found between the group with GFD and the negative. The same trend was observed for IL-6 with values in the de novo group of 2.39 μg/dL, 1.74 μg/dL in the group with gluten free diet and 1.41 μg/dL in the negative control. No significant differences were found in the analysis of RCP results. Excellent sensitivity (98.0%) and specificity (96.6%) were found in the capability of the FCP to differentiate anti-transglutaminase IgA values higher or lower than the cut-off point when the Youden index was estimated. The FCP could be considered as a possible sensitive marker to indicate intestinal inflammation in a non-invasive manner in celiac disease.


A calprotectina fecal se consolidou nos ultimos anos como um marcador util das patologias gastrointestinais. O objetivo deste estudo foi determinar os niveis de calprotectina fecal (CPF), interleucina-6 (IL-6) e proteina C-reativa (PCR) em tres grupos de pacientes; com diagnostico de novo de doenca celiaca, com diagnostico previo e dieta livre de gluten (DLG) e um grupo controle. Foram coletadas amostras de 79 pacientes entre 18 e 65 anos. Em todos os casos CPF, IL-6 e PCR foram determinadas como marcadores de inflamacao e anticorpos anti-transglutaminase IgA e anti-gliadinas desaminadas IgA e IgG como marcadores sorologicos. Valores significantemente mais altos de PCR foram detectados no grupo de novo (124,06 μg/g) comparados com o grupo com DLG (23,61 μg/g) e o grupo controle (16,91 μg/g) respectivamente. Nao foram encontradas diferencas entre o grupo com DLG e o negativo (controle). O mesmo comportamento foi observado para IL-6 com valores no grupo de novo de 2,39 μg/dL, 1,74 μg/dL no grupo com DLG e 1,41 μg/dL no controle negativo. Na analise de resultados da PCR nao foram encontradas diferencas significativas. Foram detectadas uma sensibilidade excelente (98,0%) e especificidade (96,6%) na habilidade da CPF para diferenciar valores de anti-transglutaminase IgA superiores ou inferiores ao ponto de corte quando o indice de Youden foi estimado. Poderia ser considerada a CPF como um possivel marcador sensivel para identificar inflamacao intestinal de forma nao invasiva na doenca celiaca.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Pathology , Diet, Gluten-Free , Antibodies , Immunoglobulin A , Immunoglobulin G , Celiac Disease , Interleukin-6 , Leukocyte L1 Antigen Complex , Diet
15.
Arch. endocrinol. metab. (Online) ; 64(1): 4-10, Jan.-Feb. 2020. tab
Article in English | LILACS | ID: biblio-1088773

ABSTRACT

ABSTRACT Objective The aim of this study was to investigate polycystic ovary syndrome (PCOS) and to explore the relationship between body fat percentage and metabolic markers. Subjects and methods Sedentary women were assigned to PCOS (N = 60) and CONTROL (N = 60) groups. Each group was subdivided into three subgroups according to body fat percentage (22-27%, 27-32% and 32-37%). The protocol consisted of assessments of glucose, insulin, androgens, follicle stimulating hormone (FSH), luteinizing hormone (LH), 17-hydroxyprogesterone (17-OHP), leptin, adiponectin, tumor necrosis factor (TNF-α) and interleukin-6 (IL-6). Results The PCOS subgroups showed higher concentrations of androgens, LH and 17-OHP. Leptin showed direct relationship with increased body fat percentage, whereas adiponectin showed the inverse effect. However, both were unaffected by PCOS. TNF-α and IL-6 were higher in PCOS women and showed a direct relationship with increased body fat percentage. Glucose showed direct relationship with body fat percentage, whereas insulin presented higher values in PCOS women and direct relationship with increased body fat percentage. Conclusions Our findings indicate that PCOS and body fat percentage directly influence concentrations of insulin, TNF-α and IL-6, whereas leptin and adiponectin are influenced only by the increase in body fat percentage in these women. Arch Endocrinol Metab. 2020;64(1):4-10


Subject(s)
Humans , Female , Adolescent , Adult , Young Adult , Biomarkers/blood , Adipose Tissue/anatomy & histology , Metabolic Diseases/blood , Insulin Resistance , Luteinizing Hormone/blood , Body Mass Index , Case-Control Studies , Interleukin-6/blood , Tumor Necrosis Factor-alpha/blood , 17-alpha-Hydroxyprogesterone/blood , Leptin/blood , Adiponectin/blood , Follicle Stimulating Hormone/blood , Glucose/analysis , Androgens/blood , Insulin/blood
16.
Arq. bras. cardiol ; 114(2): 268-272, Feb. 2020. tab
Article in English | LILACS | ID: biblio-1088864

ABSTRACT

Abstract Background: Periodontitis and coronary artery disease (CAD) share an inflammatory etiology; there is a recent concern regarding the investigation of an association between these two conditions. Current theories indicate that cytokines and proteins have an important role in this process. C-reactive protein and interleukin-6 are inflammatory derivatives produced in the presence of periodontitis and in the pathophysiology of coronary disease. The polymorphisms of CRP + 1444 C > T and IL6-174 G > C are recognized in the literature as being related to CAD. Objective: This study investigates the association between periodontitis and coronary artery disease, through the presence of PCR and IL-6 polymorphisms. Methods: We selected 80 patients who underwent diagnostic catheterization in the HU of UFSM. The presence of periodontitis was determined by the Community Periodontal Index, whereas the CAD was established by the medical report. DNA was collected from a saliva sample and the presence of polymorphism was determined by PCR and restriction enzymes. A significance level of 5% was adopted. Results: The mean age of all participants (p = 0.035, OR 2.65; 95%CI: (1.02-6.87) male gender (p = 0.012, OR 3.37; 95% CI: (1.28- (p = 0.013, OR 3.66; 95% CI: (1.27-10.5)), PCR polymorphism + 1444C > T (p = 0.001, OR 6.37; 95% CI:, (2.25-17.9)) and IL6 -174 G > C polymorphism (p = 0.025, OR 2.87, 95% CI: (1.09-7.55)) were statistically associated with the presence of CAD. Age > 60 years and presence of the PCR +1444 C > T polymorphism remained independently associated with CAD after adjustment by logistic regression. Conclusions: The presence of the PCR + 1444 C > T polymorphism in this study was independently associated with the presence of coronary artery disease.


Resumo Fundamento: A periodontite e a doença arterial coronariana (DAC) compartilham uma etiologia inflamatória. Existe preocupação na investigação de associação entre essas duas condições. Há citocinas e proteínas com papel importante neste processo, como a proteína C-reativa (PCR) e a interleucina 6 (IL-6), que são derivados inflamatórios produzidos na presença da periodontite e na fisiopatologia da DAC. Os polimorfismos da PCR+1444 C > T e da IL-6 -174 G > C são reconhecidos na literatura como relacionados à DAC. Objetivo: Este estudo objetiva comprovar a associação entre periodontite e DAC, através da presença dos polimorfismos da PCR e da IL-6. Métodos: Foram selecionados 80 pacientes que se submeteram ao cateterismo diagnóstico no Hospital Universitário da Universidade Federal de Santa Maria (UFSM). A periodontite foi determinada pelo índice periodontal comunitário; a DAC, pelo laudo médico. Foi coletado o ácido desoxirribonucleico (DNA) pela saliva e estabelecido o polimorfismo pela avaliação da PCR/RFLP. Foi adotado um nível de significância estatística de 5%. Resultados: A idade mediana de todos os participantes (p = 0,035; OR 2,65; IC 95% [1,02-6,87]), gênero masculino (p = 0,012; OR 3,37; IC 95% [1,28-8,9]), periodontite (p = 0,013; OR 3,66; IC 95% [1,27-10,5]), polimorfismo da PCR +1444 C > T (p = 0,001; OR 6,37; IC 95% [2,25-17,9]) e polimorfismo da IL-6 -174G > C (p = 0,025; OR 2,87; IC 95% [1,09-7,55]) foram estatisticamente relacionados à DAC. Após ajuste com a regressão logística, mantiveram-se independentemente associadas à DAC a idade maior que 60 anos e o polimorfismo da PCR +1444 C > T. Conclusões: O polimorfismo da PCR +1444 C > T, neste estudo, esteve independentemente relacionado à DAC.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Periodontitis/complications , Periodontitis/genetics , Coronary Artery Disease/complications , Coronary Artery Disease/genetics , C-Reactive Protein/genetics , Interleukin-6/genetics , Polymorphism, Single Nucleotide , Brazil , C-Reactive Protein/analysis , Logistic Models , Sex Factors , Polymerase Chain Reaction , Risk Factors , Age Factors , Interleukin-6/analysis , Alleles
17.
Rev. bras. ortop ; 55(1): 8-16, Jan.-Feb. 2020. tab, graf
Article in English | LILACS | ID: biblio-1092686

ABSTRACT

Abstract Several association studies of genes polymorphisms on estrogen receptors-α and β with respect to adolescent idiopathic scoliosis (AIS) have been published in the past two decades. However, the association with AIS, especially among different ethnic subgroups, still remains controversial. Thus, we investigated these inconclusive data by performing a meta-analysis to systematically evaluate the association. A literature search was conducted in the PubMed, ISI Web of Science, EMBASE, SCOPUS, EBSCO, Cochrane Library, China National Knowledge Infrastructure (CNKI) and Wanfang databases until January 20, 2018. The strength of relationship was assessed using odds ratios (ORs) and 95% confidence intervals (95%CIs). A total of 12 case-control studies with 4,304 cases of AIS and 3,123 controls met our criteria. The pooled ORs indicated that the ESRα XbaI A > G, ESRα PvuII T > C and ESRβ AlwNI T > C polymorphisms were not significantly associated with the risk of developing AIS in the overall analysis. However, we found a significant association between the ESRα XbaI A > G polymorphism and AIS under the homozygote model (GG versus AA; OR = 1.448, 95%CI: 1.052-1.993; p = 0.023). The present meta-analysis suggests that the ESRα XbaI A > G, ESRα PvuII T > C and ESRβ AlwNI T > C polymorphisms may not be associated with the risk of developing AIS in the overall analysis. However, ESRα XbaI A > G might have an influence on the susceptibility to develop AIS among Asians. Considering the limited sample size and ethnicity, further larger studies are needed to provide a more precise estimation of the associations.


Resumo Vários estudos de associação entre os polimorfismos genéticos nos receptores α e β de estrogênio e a escoliose idiopática da adolescência (EIA) foram publicados nas últimas duas décadas. No entanto, a associação com a EIA, especialmente em diferentes subgrupos étnicos, continua a ser controversa. Assim, o presente estudo investigou esses dados inconclusivos por meio de uma metanálise para avaliar sistematicamente essa associação. Uma pesquisa bibliográfica foi realizada nas bases de dados PubMed, ISI Web of Science, EMBASE, SCOPUS, EBSCO, Cochrane Library, China National Knowledge Infrastructure (CNKI) e Wanfang até 20 de janeiro de 2018. A força de associação foi avaliada por meio de razões de probabilidades (RPs) e intervalos de confiança de 95% (ICs95%). Um total de 12 estudos de caso-controle, com 4.304 casos de EIA e 3.123 controles, atenderam aos critérios de inclusão do presente estudo. As RPs combinadas indicaram que os polimorfismos ESRα XbaI A > G, ESRα PvuII T > C e ESRβ AlwNI T > C podem não estar significativamente associados ao risco geral de desenvolvimento de EIA. No entanto, observou-se uma associação significativa entre o polimorfismo ESRα XbaI A > G e a EIA sob o modelo homozigótico (GG versus AA; RP = 1,448; IC95%: 1,052-1,993; p = 0,023). Esta metanálise sugere que os polimorfismos ESRα XbaI A > G, ESRα PvuII T > C e ESRβ AlwNI T > C podem não estar associados ao risco geral de desenvolvimento de EIA. No entanto, ESRα XbaI A > G pode influenciar a suscetibilidade de desenvolver EIA entre indivíduos asiáticos. Considerando o tamanho e a variação étnica limitada da amostra, outros estudos de maior escala são necessários para obter uma estimativa mais precisa das associações.


Subject(s)
Polymorphism, Genetic , Scoliosis , Ethnic Groups , Interleukin-6 , Meta-Analysis , Asian Continental Ancestry Group , Genes
18.
Rev. bras. ortop ; 55(1): 17-26, Jan.-Feb. 2020. tab, graf
Article in English | LILACS | ID: biblio-1092681

ABSTRACT

Abstract Recent epidemiological studies have identified that the -174G > C (rs1800795) polymorphism in the promoter region of the interleukin-6 (IL-6) gene is associated with the risk of developing adolescent idiopathic scoliosis (AIS), but they presented inconsistent and controversial results. Thus, we performed a case-control study and meta-analysis to derive a more precise estimation of the relationship between the IL-6 -174G > C polymorphism and the risk of developing AIS. A total of 80 patients with AIS and 80 matched healthy control subjects were genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. In addition, all eligible studies published up to June 2018 were identified through a search in the PubMed, EMBASE, Google Scholar, and China National Knowledge Infrastructure (CNKI) databases. We calculated the odds ratios (ORs) and 95% confidence intervals (95%CIs) to assess the association. A total of 10 eligible studies comprising 1,695 AIS cases and 2,097 healthy controls were included in the meta-analysis. The pooled data suggested a significant association between the IL-6 -174G > C polymorphism and the susceptibility to develop AIS, which was demonstrated under 4 genetic models, that is, the allelic (C versus G; OR = 0.671; 95%CI: 0.457-0.985; p = 0.042), heterozygous (CG versus GG; OR = 0.734; 95%CI: 0.554-0.973; p = 0.032), dominant (CC + CG versus GG; OR = 0.660; 95%CI: 0.440-0.990; p = 0.044) and recessive models (CC versus CG + GG; OR = 0.506; 95%CI: 0.264-0.970; p = 0.040). The stratification analysis by ethnicity revealed an increased risk of developing AIS in Caucasians, but not in Asians. The present meta-analysis, which is inconsistent with the previous meta-analysis, suggests that the IL-6 -174G > C polymorphism may increase the individual susceptibility to develop AIS, especially in Caucasians, and it could serve as a biomarker to predict the population at high risk of developing AIS.


Resumo Estudos epidemiológicos recentes identificaram que o polimorfismo -174G > C (rs1800795) na região promotora do gene interleucina-6 (IL-6) está associado ao risco de desenvolver escoliose idiopática da adolescência (EIA), mas apresentaram resultados inconsistentes e controversos. Assim, realizamos um estudo de caso-controle e metanálise para obter uma estimativa mais precisa da relação entre o polimorfismo IL-6 -174G > C e o risco de desenvolver EIA. Um total de 80 pacientes com EIA e 80 controles saudáveis pareados foram genotipados usando o ensaio de reação em cadeia de polimerase de polimorfismos de comprimento de fragmentos de restrição (RCP-PCFR). Além disso, todos os estudos elegíveis publicados até junho de 2018 foram identificados por meio de uma pesquisa nas bases de dados PubMed, EMBASE, Google Scholar e China National Knowledge Infrastructure (CNKI). Calculamos as razões de probabilidades (RPs) e os intervalos de confiança de 95% (ICs95%) para avaliar a associação. Um total de 10 estudos elegíveis compreendendo 1.695 casos de EIA e 2.097 controles saudáveis foram incluídos na metanálise. Os dados agrupados sugeriram uma associação significativa entre o polimorfismo IL-6 -174G > C e a suscetibilidade a desenvolver EIA que foi demonstrada em quatro modelos genéticos, ou seja, alélico (C versus G; RP = 0,671; IC95%: 0,457-0,985; p = 0,042), heterozigótico (GC versus GG; RP = 0,734; IC95%: 0,554-0,973; p = 0,032), dominante (CC + GC versus GG; RP = 0,660; IC95%: 0,440-0,990; p = 0,044) e recessivo (CC versus CG + GG; RP = 0,506; IC95%: 0,264-0,970; p = 0,040). A análise de estratificação por etnia revelou um aumento do risco de desenvolver EIA em caucasianos, mas não em asiáticos. Esta metanálise, que é inconsistente com relação à metanálise anterior, sugere que o polimorfismo IL-6 -174G > C pode aumentar a suscetibilidade individual para desenvolver EIA, especialmente em caucasianos, e pode servir como um biomarcador para prever a população com alto risco de desenvolver EIA.


Subject(s)
Humans , Male , Female , Polymorphism, Genetic , Scoliosis , Interleukin-6 , Meta-Analysis
19.
J. Health Biol. Sci. (Online) ; 8(1): 1-4, 01/01/2020. ilus
Article in English | LILACS | ID: biblio-1103710

ABSTRACT

Introduction: IL-6 is a cytokine that participates in the systemic inflammatory process in Kala-azar, its plasma levels are high during active disease and especially in patients with severe clinical condition. Case reports: Three patients from different age groups, clinical score of severe disease and different plasma levels of IL-6 were reported. Conclusion: The results suggest that only the clinical severity score does not present sensitivity to classify, among critically ill patients, those with imminent risk of death. The IL-6 concentration seems to allow this differentiation, considering that the only fatal case, HBV/Leishmania coinfection, presented an expressively higher plasma level.


Introdução: IL-6 é uma citocina que participa do processo inflamatório sistêmico no calazar. Seus níveis plasmáticos estão elevados durante doença ativa e, principalmente, em pacientes com quadro clínico grave. Relato de casos: foram reportados três pacientes em diferentes faixas etárias, escore clínico de doença grave e diferentes níveis plasmáticos de IL-6. Conclusão: os resultados sugerem que apenas o escore clínico não apresenta sensibilidade para classificar, entre os doentes graves, aquele com risco iminente de óbito. A concentração de IL-6 parece permitir essa diferenciação, considerando que o único caso fatal, coinfecção HBV/Leishmania, mostrou nível plasmático expressivamente mais elevado.


Subject(s)
Coinfection , Interleukin-6 , Hepatitis B , Leishmaniasis, Visceral
20.
Clinics ; 75: e1801, 2020. tab, graf
Article in English | LILACS | ID: biblio-1133464

ABSTRACT

Interleukin-6 (IL-6) plays a crucial role in systemic autoimmunity and pathologic inflammation. Numerous studies have explored serum IL-6 levels in systemic lupus erythematosus (SLE) and their correlation with disease activity. Here, we performed a meta-analysis to quantitatively assess the correlation between the serum IL-6 levels and SLE activity. The PubMed and EMBASE databases were thoroughly searched for relevant studies up to September 2019. Standardized mean differences (SMDs) with 95% confidence intervals (95% CIs) were used to describe the differences between serum IL-6 levels in SLE patients and healthy controls and between those in active SLE patients and inactive SLE patients. The correlation between the serum IL-6 levels and disease activity was evaluated using Fisher's z values. A total of 24 studies involving 1817 SLE patients and 874 healthy controls were included in this meta-analysis. Serum IL-6 levels were significantly higher in SLE patients than in the healthy controls (pooled SMD: 2.12, 95% CI: 1.21-3.03, Active SLE patients had higher serum IL-6 levels than inactive SLE patients (pooled SMD: 2.12, 95% CI: 1.21-3.03). Furthermore, the pooled Fisher's z values (pooled Fisher's z=0.36, 95% CI: 0.26-0.46, p<0.01) showed that there was a positive correlation between the serum IL-6 levels and SLE activity. This study suggested that serum IL-6 levels were higher in patients with SLE than in healthy controls, and they were positively correlated with disease activity when Systemic Lupus Erythematosus Disease Activity Index>4 was defined as active SLE. More homogeneous studies with large sample sizes are warranted to confirm our findings due to several limitations in our meta-analysis.


Subject(s)
Humans , Interleukin-6 , Lupus Erythematosus, Systemic
SELECTION OF CITATIONS
SEARCH DETAIL